Insights
Chinese drugmakers weigh options as US mulls pharma tariffs
With Trump floating tariffs on medicine, suppliers are weighing upgrades, relocation, and, for some, the exit.
36kr_en@kr-asia.com
36Kr is China's most influential business and technology network, delivering high-quality content focused on China’s innovation and new economy trends since 2010. With its extensive traffic and network, 36Kr has built a comprehensive database and strong data analytics capabilities to provide insights into China’s technology landscape.
Insights
With Trump floating tariffs on medicine, suppliers are weighing upgrades, relocation, and, for some, the exit.